Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract

cited authors

  • Azad, Arun; Fizazi, Karim; Laird, Douglas; Matsubara, Nobuaki; De Giorgi, Ugo; ButtIgliero, Consuelo; Karsh, Lawrence Ivan; Joung, Jae Young; Yip, Steven; Zschaebitz, Stefanie; Albacker, Lee A.; Healy, Cynthia G.; Lin, Xun; Chelliserry, Jijumon; Agarwal, Neeraj

authors

Publication Date

  • June 1, 2024

webpage

published in

category

volume

  • 42

issue

  • 16